April 2nd 2024
Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Advances in the Systemic Treatment of Metastatic Melanoma
May 15th 2013Within the relatively short time that ipilimumab and vemurafenib have been commercially available, phase II data for the investigational agents nivolumab and MK-3475, for the combination of dabrafenib and trametinib, and for adoptive cell therapy strongly suggest even further improvements in treatment outcomes.
Gene Associated With Obesity Linked to Melanoma
March 13th 2013The FTO gene, which prior research has shown is strongly associated with obesity and body mass index (BMI), contains variants associated with an increased risk for malignant melanoma, according to the results of a genome-wide association study conducted by the GenoMEL consortium.
MicroRNA-18b May Act as Tumor Suppressor in Melanoma
February 12th 2013Preclinical analyses have indicated that microRNA-18b may have a role as a tumor suppressor, has the potential to be a biomarker for melanoma, and its overexpression may be a novel therapeutic strategy for the treatment of melanoma.
Tremelimumab No Match vs Metastatic Melanoma Standard of Care
January 17th 2013The anti–cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) antibody tremelimumab failed to achieve a significant improvement in survival among patients with metastatic melanoma compared with the standard of care treatments used in the comparator arm, according to the results of a phase III study.
Adding Sorafenib to Chemo Combo Fails to Improve Metastatic Melanoma Survival
January 3rd 2013No improvement in overall survival was seen in patients with metastatic melanoma who were assigned treatment with sorafenib in combination with carboplatin/paclitaxel for the treatment of their disease, according to the results of a double-blind, phase III study.
Advances in the Management and Treatment of Metastatic Melanoma
November 12th 2012In this podcast we discuss the recent advances in the management and treatment of metastatic melanoma with Jeffrey Sosman, MD, medical oncologist and director of the Melanoma and Tumor Immunotherapy Program at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.
Relative Roles of Targeted Therapies and Immunotherapies in Melanoma
October 23rd 2012In this interview, Dr. Mario Sznol shares unique insights into two treatment approaches for melanoma--targeted therapies and a drug that targets the Programmed Death 1 pathway-including how they compare and how they might be combined.
Targeted Therapy: Its Status and Promise in Selected Solid Tumors Part I
October 23rd 2012We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling pathways in the heterogeneous tumors of mesenchymal origin-spurred by the identification of c-Kit–activating mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the tyrosine kinase inhibitor imatinib (Gleevec).
ESMO: BRAF/MEK Inhibitor Combo Bests Monotherapy for Metastatic Melanoma
October 3rd 2012Phase II results presented at the ESMO 2012 Congress showed a 3.6-month improvement in progression-free survival for patients receiving both dabrafenib plus trametinib compared to those receiving dabrafenib alone.
Use of SPECT/CT in Melanoma Discovered More Sentinel Lymph Node Metastatic Involvement
September 23rd 2012Patients with node-negative melanoma undergoing sentinel lymph node excision who were given preoperative imaging with SPECT/CT experienced a higher frequency of metastatic involvement and a longer disease-free survival compared to those without preoperative SPECT/CT.
New ASCO, SSO Guidelines for Sentinel Lymph Node Biopsy in Melanoma
August 17th 2012Sentinel lymph node biopsy is recommended for patients with newly diagnosed intermediate-thickness melanomas, while the procedure may not be indicated for patients with thinner lesions, according to a new set of guidelines.
New Therapeutic Target, MDM4, Found in Cutaneous Melanoma
July 24th 2012A new target of melanoma tumors has been identified that may be promising as part of a novel combination therapy for melanoma. In a study published in Nature Medicine, researchers have identified that more than half of melanoma cases, both early and late-stage, may have higher levels of MDM4, a p53-interacting protein.
Melanoma at ASCO: Latest Treatments and Emerging Therapies
June 11th 2012In this exclusive interview, Michael B. Atkins, MD, director of the Georgetown Lombardi Comprehensive Cancer Center, discusses some of the most important melanoma research to come out of this year’s ASCO meeting and talks about the future of melanoma therapies.
ASCO: Expert Panel Explores Questions Regarding Drug Selection, Drug Sequencing in Advanced Melanoma
June 3rd 2012The new therapies that became available for advanced melanoma over the past year-the anti-CTLA4 antibody ipilimumab (Yervoy) and the selective BRAF inhibitor vemurafenib (Zelboraf)-represent promising new options for these patients, whose prognosis was heretofore almost universally dismal. However, the advent of new treatment strategies has made treatment decisions more complex.
PREX2, New Melanoma Mutation Identified
May 10th 2012Melanoma has become the poster cancer for genomic research. The identification of a driver mutation in the BRAF gene found in approximately 40% of metastatic melanoma patients and the subsequent approval last year of the targeted BRAF inhibitor, vemurafenib, has resulted in a surge of both clinical and laboratory research.